Bapineuzumab had no health risk found for lower doses but the ones at a higher dose never started, although the efficacy of drugs targeted to brain plaques (neuritic plaques) is being questioned.
Bapineuzumab was the first antibody to be found to cause amyloid-related imaging abnormalities, including an accumulation of fluid in brain tissue (ARIA-E) in patients receiving the highest dose. 
